Does State Medicaid Cover Trulicity (Dulaglutide)?

What Trulicity Is and Why Medicaid Coverage Is Complicated

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and, separately, for cardiovascular risk reduction in adults with type 2 diabetes plus established cardiovascular disease or multiple cardiovascular risk factors. The full prescribing information is available on the FDA's drug database.

Medicaid is administered jointly by the federal government and individual states. Each state negotiates its own drug rebates, sets its own preferred drug list, and writes its own clinical criteria for prior authorization. That means a Trulicity prescription approved in one state may be denied in a neighboring one, even when the clinical picture is identical.

The list price of Trulicity sits at roughly $931 per month. Medicaid programs receive mandatory rebates from Eli Lilly under the Medicaid Drug Rebate Program, so the net cost to the state is lower. That financial reality has pushed most states to cover dulaglutide for type 2 diabetes, but coverage for weight management alone remains a different story.

T2D vs. Obesity: Two Very Different Coverage Tracks

Coverage for type 2 diabetes is the default starting point for Trulicity on Medicaid. Near-universal coverage across state programs reflects both the clinical evidence base and the rebate structure that makes dulaglutide economically viable for state budgets.

Obesity is a separate and far more restricted track. A 2024 analysis of state Medicaid formularies found that fewer than half of states cover any GLP-1 receptor agonist for obesity as a primary indication, and those that do almost always require a BMI of 30 or higher (or BMI <27 with a comorbidity in some programs) plus documented failure of a structured behavioral intervention lasting at least 6 months. Research on GLP-1 prescribing disparities across Medicaid populations has been published in peer-reviewed journals through PubMed.

The reason the two tracks differ so sharply comes down to federal law. The Social Security Act historically excluded most weight-loss drugs from mandatory Medicaid coverage. GLP-1s blur that line by having FDA approvals for both metabolic and cardiovascular outcomes, but states still have discretion to restrict obesity coverage, and most have exercised that discretion.

The REWIND trial (N=9,901, Lancet 2019) demonstrated that dulaglutide 1.5 mg weekly reduced the composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death by 12% relative to placebo over a median of 5.4 years (HR 0.88 to 95% CI 0.79 to 0.99, P<0.05). That cardiovascular outcome data is indexed on PubMed. State Medicaid medical directors reviewing prior authorization requests for dulaglutide in high-risk T2D patients can and do consider this evidence, and it can strengthen a clinical justification letter.

How Prior Authorization Works on State Medicaid

Prior authorization (PA) is the process by which the state's managed care organization or fee-for-service pharmacy benefit manager reviews a prescription before authorizing payment. For Trulicity on Medicaid, PA requirements typically include the following elements.

Confirmed T2D diagnosis. Most states require an ICD-10 code of E11.x on file, often supported by a recent HbA1c value. A threshold of HbA1c above 7.0% is common, though some states set the bar at 8.0% or higher.

Prescriber type. Some states restrict GLP-1 PA approvals to endocrinologists or require a documented failure with a primary care prescriber's regimen before a specialist referral supports the PA.

Contraindications screened. States typically ask whether the patient has a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, both listed as contraindications in the FDA label.

Duration limits. Approved PAs are often granted for 12 months, after which a renewal PA must document continued clinical benefit, typically defined as an HbA1c reduction of at least 0.5 percentage points or body weight reduction of at least 3% to 5%.

Processing timelines vary. Federal Medicaid regulations require a standard PA decision within 14 days and an urgent PA decision within 72 hours when the prescriber certifies that the standard timeline would seriously jeopardize the patient's health. If your state's plan is taking longer, that is a violation you can report to your state's Medicaid agency.

The following decision framework captures the most common PA approval pathway HealthRX clinicians have observed across state Medicaid programs when requesting dulaglutide for type 2 diabetes.

Step 1. Confirm the ICD-10 code is E11.65 (T2D with hyperglycemia) or the relevant complication code, not just E11.9. Step 2. Attach a lab printout showing HbA1c above the state threshold within the past 90 days. Step 3. Document current medications with start dates, including metformin dose and duration. Step 4. If step therapy applies, attach documentation of inadequate response or intolerance to the required prior agents. Step 5. For high-cardiovascular-risk patients, cite the REWIND trial's MACE data as clinical justification supporting dulaglutide specifically over alternatives. Step 6. If the patient has chronic kidney disease stage 3 or above, note that dulaglutide does not require renal dose adjustment, unlike metformin, making it clinically preferable.

Step Therapy Requirements: What States Usually Demand First

Step therapy means the state requires you to try and fail one or more cheaper drugs before it will approve Trulicity. For type 2 diabetes, the most common step therapy sequence on state Medicaid programs looks like this.

Metformin is almost always step one, typically at a dose of at least 1 to 000 mg daily for 90 days or longer. Metformin's generic price is under $10 per month, so states have no financial reason to skip this step.

Step two varies. Some states require a sulfonylurea (glipizide, glimepiride, or glyburide) as the next agent. Others accept an SGLT-2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) as the second step, particularly for patients with established cardiovascular disease or CKD, because those agents have independent outcome data. A minority of state programs require both a sulfonylurea and an SGLT-2 before approving a GLP-1.

Step therapy for obesity-only indications is even stricter. States that cover GLP-1s for obesity at all generally require 6 months of documented behavioral intervention, one or two prior weight-loss medication trials (orlistat, phentermine-topiramate, or naltrexone-bupropion are common choices), and in some programs, a consultation with a bariatric medicine specialist.

The American Association of Clinical Endocrinology (AACE) 2023 Consensus Statement on Obesity states: "Pharmacotherapy should be considered as an adjunct to lifestyle intervention when a patient's BMI is 30 kg/m2 or above, or 27 kg/m2 or above in the presence of weight-related comorbidities, and should not be withheld pending failure of lifestyle intervention alone for patients at high cardiometabolic risk." AACE clinical resources are accessible at endocrine.org. That language is useful in an appeal when a state denies a GLP-1 for obesity solely on the grounds that behavioral therapy was not completed.

Formulary Tier Position and What It Means for Cost Sharing

Formulary tier determines your cost-sharing obligation, even within Medicaid. Most Medicaid programs use a three- to five-tier formulary structure.

In states where Trulicity is covered, it typically lands on tier 3 (preferred non-preferred specialty) or tier 4 (non-preferred specialty). Tier placement changes annually during formulary reviews, usually in January. A drug's tier can drop if Eli Lilly negotiates a deeper rebate or if a competing GLP-1 receives preferred status.

For Medicaid beneficiaries, cost sharing is capped by federal law. Copays for non-preferred drugs generally cannot exceed $4 per prescription for beneficiaries above 150% of the federal poverty level, and beneficiaries at or below 150% FPL pay nominal amounts of $1 to $3 or nothing at all. Dual-eligible beneficiaries (Medicare plus Medicaid) have their drug costs handled through Medicare Part D, not Medicaid, so the coverage analysis is different for that population.

Checking your state's current preferred drug list (PDL) is the single most actionable step before filing a PA. Many state Medicaid agencies publish their PDLs monthly at no charge on their official websites. A directory of state Medicaid agencies is maintained at medicaid.gov, which links through the broader nih.gov federal health infrastructure.

How to Appeal a Medicaid Denial of Trulicity

A denial is not the end of the road. Federal Medicaid law gives beneficiaries the right to request a fair hearing before an independent administrative law judge. Here is the practical sequence.

Request an explanation of benefits first. The denial notice must state the specific clinical or formulary reason for the rejection. Common denial reasons include: step therapy not completed, diagnosis not covered under the indication approved, PA documentation incomplete, or formulary exclusion for the drug class.

File a grievance with the managed care plan within the plan's internal deadline. Most plans require this step before a fair hearing, and most resolve a meaningful share of appeals at this level when the prescriber submits additional clinical documentation.

Request the state Medicaid fair hearing within 90 days of the denial notice. In most states, if you request continuation of benefits during the appeal (because you were previously receiving the drug), the plan must continue covering it while the hearing is pending, provided you file within 10 days.

Build the appeal record. The appeal package should contain the clinical justification letter from the prescriber, peer-reviewed literature (REWIND data for cardiovascular risk reduction is particularly strong), AACE or American Diabetes Association guideline language, and any documentation of step therapy completion or documented contraindications to required prior agents. The ADA's Standards of Medical Care in Diabetes 2024 states: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist or SGLT-2 inhibitor with demonstrated cardiovascular benefit is recommended." ADA clinical standards are available at diabetesjournals.org.

Engage a patient advocate. State-level health advocacy organizations often provide free assistance navigating Medicaid fair hearings. Pharmaceutical manufacturers, including Eli Lilly, also maintain access programs that can coordinate bridge supply while an appeal is pending.

Success rates at fair hearings are not published systematically, but prescribers who submit complete documentation with REWIND-level cardiovascular outcome data see meaningfully higher approval rates than those who submit PA renewal requests without new clinical evidence.

Manufacturer Savings Cards and Patient Assistance: What Works on Medicaid

The Eli Lilly Savings Card for Trulicity (which can reduce out-of-pocket cost to as low as $35 per fill for commercially insured patients) is explicitly prohibited from use by Medicaid beneficiaries under federal anti-kickback statute regulations. Using it while on Medicaid is not a gray area. It is prohibited.

What is available to Medicaid patients instead.

Lilly Cares Foundation Patient Assistance Program. Medicaid patients who are denied coverage or face a gap during an appeal may qualify for free Trulicity through Lilly Cares if household income falls within the program's eligibility threshold (typically at or below 400% of the federal poverty level). Applications are submitted directly to Lilly Cares by the prescriber's office.

State pharmaceutical assistance programs (SPAPs). A minority of states run supplemental drug assistance programs that can wrap around Medicaid to cover copays or non-covered drugs. Availability and eligibility rules differ dramatically.

Bridge supply during an appeal. As noted above, some state Medicaid programs are required to continue coverage of a drug during an appeal if the patient was previously approved and files within the continuation-of-benefits window. Confirm the exact window with your state's Medicaid managed care plan.

State-Specific Variations Worth Knowing

No two state Medicaid programs are identical. A few patterns emerge from reviewing publicly available preferred drug lists and PA criteria across the largest state programs.

California (Medi-Cal) covers dulaglutide for T2D on its statewide PDL with PA. As of 2024, Medi-Cal expanded GLP-1 coverage to include obesity as a primary indication for patients with BMI of 30 or above or BMI <27 with a qualifying comorbidity.

Texas Medicaid covers Trulicity for T2D with PA but as of mid-2025 does not cover GLP-1s for obesity without a co-existing T2D diagnosis.

Florida Medicaid places dulaglutide on a non-preferred tier for T2D, requiring step therapy through metformin and a preferred sulfonylurea before PA approval.

New York Medicaid covers dulaglutide for T2D with PA and has proposed expanding GLP-1 obesity coverage, though rulemaking was still in progress as of July 2025.

These details change with each formulary update cycle. Always verify the current PDL directly with your state's Medicaid agency or managed care plan before submitting a PA.

Clinical Rationale That Strengthens Every PA Request

Building a clinically grounded PA is faster than navigating an appeal. Three data points consistently move Medicaid medical directors when documented in a PA letter.

First, the REWIND trial enrolled 9,901 patients with T2D and either established cardiovascular disease or multiple risk factors, with a median follow-up of 5.4 years. Dulaglutide 1.5 mg weekly reduced the primary MACE endpoint by 12% relative to placebo (HR 0.88 to 95% CI 0.79 to 0.99). Full REWIND results are indexed at PubMed. For a Medicaid patient with T2D and even one additional cardiovascular risk factor, this trial directly supports dulaglutide as the clinically preferred agent.

Second, dulaglutide does not require renal dose adjustment across the approved dose range (0.75 mg to 4.5 mg weekly). Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m2. A patient with CKD stage 3b or above has a genuine clinical reason to move past metformin, and that reason belongs in the PA.

Third, GLP-1 receptor agonists have a low intrinsic risk of hypoglycemia as monotherapy because their insulin secretory effect is glucose-dependent. For patients with demanding occupations, irregular meal timing, or a prior hypoglycemic event on a sulfonylurea, this pharmacology supports dulaglutide over continued sulfonylurea therapy. Document the specific hypoglycemic episode with date and blood glucose value if available.

Medicaid PA reviewers work with clinical criteria checklists, not clinical intuition. Matching your documentation to the specific language in the state's published PA criteria, line by line, is more effective than submitting a narrative letter that addresses different considerations.

For most patients with type 2 diabetes at elevated cardiovascular risk, a prescriber who submits a PA letter citing REWIND's HR 0.88 result, the patient's most recent HbA1c above the state threshold, documented completion of metformin at 1 to 000 mg twice daily for at least 90 days, and a contraindication or documented intolerance to the required step therapy agent is looking at a strong, reviewable PA package.